# South Korea Biomarker Technologies Market

> South Korea Biomarker Technologies Market Research Report: By Product (Consumables, Instruments), By Profiling Technology (PCR, Imaging Technology, NGS), By Application (Cancer, Infectious Disease) andBy Research Area (Genomics, Proteomics)- Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.01%
- **2018:** $ 695.49 Million
- **2024:** $ 0.75 Billion
- **2035:** $ 1.75 Billion
- **Key Players:** Samsung Biologics (KR), LG Chem (KR), Celltrion (KR), Hanmi Pharmaceutical (KR), SK Biopharmaceuticals (KR), Genexine (KR), Medytox (KR), Korea United Pharm (KR), Daewoong Pharmaceutical (KR)

**Report ID:** MRFR/HC/54482-HCR · **Pages:** 200 · **Author:** Vikita Thakur · **Last Updated:** May 12, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-biomarker-technologies-market-56248

---

## Market Summary

**South Korea Biomarker Technologies Market Overview****:**

**As per MRFR analysis, the South Korea Biomarker Technologies Market Size was estimated at 695.49 (USD Million) in 2023.****The South Korea Biomarker Technologies Market Industry is expected to grow from 751.2(USD Million) in 2024 to 1,502.4 (USD Million) by 2035. The South Korea Biomarker Technologies Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035).**

**Key South Korea Biomarker Technologies Market Trends Highlighted**

The South Korea Biomarker Technologies Market is showing notable changes and shifts. One of the most important market motivators is the growing attention paid to personalized medicine. The South Korean government is funding healthcare vigorously, increasing expenditures in biomarker research and development in south Korea technologies to improve diagnostics and therapeutics for diseases. This impetus is in consonance with other health policies of the country aimed at improving health outcomes of the population, especially in relation to chronic illnesses. There are also increasing market opportunities owing to the increasing synergetic activities between academic institutions and biotech companies.

South Korea’s sophisticated research output internationally, especially in South Korea boasts a strong research South Korea is fortified with its university system and research supporting institutes which are tackling innovative challenges in the field of biomarker technologies. The US aided initiatives to stimulate PPPs are equally important as they make easier for innovative for start-ups. It helps to bring out in many ways innovative ideas which have the recently observed trends of the increase in the use of advanced technology innovations like Artificial intelligence and Big data analytical tools in the fields of biomarkers. South Korean firms have started adopting such technology to improve the quality and efficiency of biomarker identification and validation methods.

In addition, the newly enacted regulations that seek to speed up the approvals for diagnostics based on biomarkers indicate the country’s efforts towards making novel healthcare services available to the people. As a whole, these developments showcase the unique and fast-growing environment for biomarker technologies in Korea where technology, government initiatives, and cooperation in research work together.

**South Korea Biomarker Technologies Market Drivers**

Rising Prevalence of Chronic Diseases

The South Korea Biomarker Technologies Market Industry is significantly driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and heart diseases. Current statistics indicate that in South Korea, the cancer incidence rate is projected to rise by approximately 10% over the next decade, with the number of new cancer cases reaching around 250,000 annually by 2030 according to the Ministry of Health and Welfare. This surge in chronic diseases necessitates advanced biomarker technologies for diagnosis and personalized treatment options, pushing healthcare providers to invest in research and solutions.Established organizations, such as Samsung Medical Center and Seoul National University Hospital, are at the forefront of adopting these technologies, thereby facilitating rapid advancements in the South Korea Biomarker Technologies Market Industry. Moreover, the government's commitment to enhancing healthcare infrastructure further supports this growth trend.

Advancements in Genomics and Proteomics

The South Korea Biomarker Technologies Market Industry is also propelled by significant advancements in genomics and proteomics. With rapid progress in sequencing technologies, the cost of genomic sequencing has decreased dramatically, by nearly 90% over the last decade. This reduction encourages more healthcare institutions in South Korea to integrate biomarker technologies into clinical practice. The Korea Advanced Institute of Science and Technology (KAIST) is one of the leading institutions driving research innovations in this field.As organizations like KAIST continue to develop novel biomarker assays, the South Korea Biomarker Technologies Market Industry is poised for exponential growth, supporting precision medicine and improved patient outcomes.

Government Initiatives and Funding

The South Korean government is actively promoting research in biomarker technologies through funding programs and initiatives. The Ministry of Science and ICT has announced a funding scheme of approximately USD 500 million for biotechnology research over the next five years, aimed specifically at enhancing diagnostic technologies and treatments. This substantial investment is expected to accelerate the development and commercialization of biomarker technologies, facilitating collaborations between academic institutions and private industry.The sustained government support lays a strong foundation for the South Korea Biomarker Technologies Market Industry to thrive, as it encourages innovation, research initiatives, and commercial applications.

Increasing Demand for Personalized Medicine

The demand for personalized medicine in South Korea is rising exponentially, driven by the need for more accurate disease diagnosis and tailored treatment plans. With approximately 50% of patients expressing preferences for personalized treatment based on their genetic profiles, there is a notable shift in healthcare paradigms. Established organizations such as Hyundai Pharmaceutical Company are integrating biomarker technologies into their research programs, enabling the development of personalized medication that addresses individual patient needs.As awareness and acceptance of personalized medicine grow, the South Korea Biomarker Technologies Market Industry is expected to expand, with significant investments flowing into innovative biomarker development projects to meet patient expectations.

**South Korea Biomarker Technologies Market Segment Insights****:**

**Biomarker Technologies Market Product Insights**

The South Korea Biomarker Technologies Market reflects considerable potential in the Product segment, focusing on advanced solutions essential for diagnostics and therapeutic outcomes. Given the expected growth trajectory, it is evident that the market fosters substantial innovations, particularly through its primary components: Consumables and Instruments. Consumables, often regarded as vital tools within laboratories, represent a multitude of reagents, kits, and other essential items that are critical for research and diagnostic applications. The increasing demand for precision medicine and personalized therapies predominantly drives this area, significantly influencing research and development initiatives among institutions across South Korea.Instruments play an equally important role, comprising sophisticated devices used in biomarker analysis, including assays and imaging systems. The notable advancements in instrumentation technology are propelling the efficiency and accuracy of biomarker detection and quantification processes. This segment is complemented by a robust ecosystem of regulatory frameworks and support from government initiatives aimed at enhancing research capabilities within the biotechnology sphere. The South Korean government has been proactive in fostering innovation and investment in healthcare technologies, thereby creating an environment conducive to growth in the biomarker technologies sector.Collectively, the Consumables and Instruments play a crucial role by not only responding to the rising healthcare demands but also empowering the biotechnology industry to address broader challenges such as fast-tracking diagnostics and personalized treatment solutions. These dynamics position the South Korea Biomarker Technologies Market as a key contributor to the overall healthcare landscape, indicating a significant shift towards more precise and targeted biomarker applications. In the context of global health, the focus on improving population health outcomes through these advanced technologies illustrates their critical relevance in addressing existing and emerging health challenges faced by modern society.With continued investment and support, the outlook for the Product segment within the South Korea Biomarker Technologies Market remains poised for substantial growth, showcasing its importance in revolutionizing healthcare delivery and enhancing patient care outcomes significantly.

**Biomarker Technologies Market Profiling Technology Insights**

The Profiling Technology segment of the South Korea Biomarker Technologies Market is pivotal in advancing personalized medicine and diagnostics. It encompasses essential techniques such as Polymerase Chain Reaction (PCR), Imaging Technology, and Next-Generation Sequencing (NGS), each playing a crucial role in disease detection and analysis. PCR's sensitivity in amplifying DNA has made it a staple in various genomic applications, significantly aiding in the rapid diagnosis of infectious diseases. Imaging Technology enhances the visualization of biological processes, allowing for more precise disease monitoring and treatment efficacy evaluation.NGS has revolutionized genomics by enabling comprehensive analysis of genetic variation, thus supporting targeted therapies and treatment plans. The increasing demand for early disease detection and tailored treatment options is driving growth in these technologies within the South Korea Biomarker Technologies Market landscape. Market trends indicate a notable shift towards workflows that integrate these profiling techniques, enhancing their combined effectiveness and operational efficiency. As the healthcare system in South Korea continues to invest heavily in Research and Development, the Profiling Technology segment is set to play an integral role in shaping the future of medical diagnostics and personalized healthcare strategies.

**Biomarker Technologies Market Application Insights**

The South Korea Biomarker Technologies Market is experiencing substantial growth, particularly within the Application segment, which encompasses critical areas such as Cancer and Infectious Disease. The importance of Cancer diagnostics and treatment development is pronounced, as South Korea prioritizes advancements in precision medicine to improve patient outcomes. With a substantial portion of the population affected by various cancer types, the market is responding with innovative biomarkers that facilitate early detection and tailored therapies.Similarly, the growing burden of Infectious Diseases, especially in light of recent global health challenges, highlights the need for enhanced diagnostic tools and surveillance systems. Biomarkers play a pivotal role in early identification and management of these diseases, thus ensuring timely interventions. The emphasis on Research and Development in these areas is fueled by government initiatives aiming to enhance healthcare infrastructure and innovation. Such focus on developing robust biomarker technologies is leading to significant opportunities for growth and advancements in both cancer and infectious disease diagnostics, contributing positively to the overall market dynamics in South Korea.

**Biomarker Technologies Market Research Area Insights**

The South Korea Biomarker Technologies Market exhibits an evolving landscape, particularly within the Research Area surrounding advancements in Genomics and Proteomics. As the nation strengthens its focus on precision medicine, Genomics plays a pivotal role in understanding genetic variations linked to diseases, thereby significantly impacting drug development and personalized treatment strategies. This increased emphasis on genetic profiling aligns with South Korea's commitment to enhancing healthcare outcomes and tackling complex diseases. Meanwhile, Proteomics, the large-scale study of proteins, remains crucial for identifying biomarkers that can indicate disease states, leading to improved diagnostic tools and therapeutic approaches.The integration of these technologies into healthcare research not only enhances disease detection but also fuels innovation within the biotechnology sector, addressing both local and global healthcare challenges. The combined advancements in Genomics and Proteomics are vital drivers steering the South Korea Biomarker Technologies Market towards a future characterized by improved healthcare delivery and patient outcomes. The increasing governmental support for biotechnological research further accelerates the development trajectory of these critical segments, creating ample opportunities for collaboration and growth in this dynamic market environment.

**South Korea Biomarker Technologies Market Key Players and Competitive Insights****:**

The South Korea Biomarker Technologies Market is characterized by a rapidly evolving landscape driven by advancements in biomedical research, personalized medicine, and innovative diagnostic technologies. This market is influenced by a robust framework of academic institutions, research centers, and healthcare organizations that collaborate to enhance biomarker discovery and application. The competitive dynamics in this market reflect a blend of established firms and emerging companies focused on developing novel biomarker solutions that enhance disease detection, treatment monitoring, and therapeutic outcomes. As healthcare technologies progress, the competition also emphasizes strategic partnerships and technological alliances, aimed at accelerating research and commercialization processes. In the context of the South Korea Biomarker Technologies Market, Korea Biobank stands out with its comprehensive resources and capabilities that significantly influence the biobanking landscape. The strengths of Korea Biobank lie in its extensive repository of biological samples and associated clinical data, which are invaluable for research and development activities focused on biomarkers. The organization's robust collaborations with various research institutes and universities enable it to maintain a strong foothold in the biomarker technology sector. Moreover, its commitment to maintaining high standards in sample integrity and data management enhances its attractiveness as a biobanking partner, providing researchers with reliable resources that support groundbreaking studies and innovations in biomarker technology.Medytox also plays a pivotal role in the South Korea Biomarker Technologies Market, particularly through its development and commercialization of biopharmaceutical products. The company's key offerings include innovative therapeutic solutions that leverage advanced biomarker technologies for condition-specific treatment approaches. Medytox has established a notable market presence, bolstered by its engineering capabilities and a pipeline of promising products aimed at addressing unmet medical needs. The company's strategic focus on forming alliances and engaging in mergers and acquisitions has further solidified its position within the market, enabling access to new technologies and expanding its product portfolio. By leveraging its strengths in research and development, Medytox not only contributes significantly to therapeutic advances but also enhances the overall competitive landscape of the South Korea Biomarker Technologies Market.

**Key Companies in the South Korea Biomarker Technologies Market Include:**

Korea Biobank

Medytox

Lunit

Hanmi Pharmaceutical

Precision Medicine

Seegene

MediKine

LG Chem

Green Cross Corporation

Nara Biotech

Bioasis Technologies

SNUH Biomedical Research Institute

Pharmicell

Samsung Biologics

**South Korea Biomarker Technologies Market Industry Developments**

_Recent news developments in the South Korea Biomarker Technologies Market have highlighted significant advancements and increased investment in the sector. Companies like Korea Biobank and Medytox are expanding their Research and Development efforts to enhance biomarker discovery and diagnostics. Lunit announced collaborations aimed at advancing AI and imaging technologies, aiming to optimize cancer diagnostics. In July 2023, Hanmi Pharmaceutical made notable strides with new biomarker-based therapies targeting specific conditions. Seegene also continues to grow, focusing on diagnostic innovations amidst rising demand.____Current affairs indicate a competitive landscape with medtech firms such as MediKine and LG Chem enhancing their molecular diagnostic solutions. Green Cross Corporation is making efforts in vaccine and__therapeutic developments associated with biomarkers. Notably, in September 2023, Samsung Biologics entered a strategic partnership with Nara Biotech to co-develop innovative biomarker-based technologies. The continuous growth in market valuation is supported by the increasing need for precision medicine, which drives investments in biomarker technologies. Over the last few years, substantial emphasis on genetic research, evidenced by collaborations and funding in bioanalytics, has fueled advancements in the South Korean biotechnology landscape._

**South Korea Biomarker Technologies Market Segmentation Insights**

**Biomarker Technologies Market Product****Outlook**

**Consumables**

**Instruments**

**Biomarker Technologies Market Profiling Technology****Outlook**

**PCR**

**Imaging Technology**

**NGS**

**Biomarker Technologies Market Application****Outlook**

**Cancer**

**Infectious Disease**

**Biomarker Technologies Market Research Area****Outlook**

**Genomics**

**Proteomics**

****

## Market Drivers

### Advancements in Genomic Research

The rapid advancements in genomic research are significantly influencing the South Korea [Biomarker](https://www.marketresearchfuture.com/reports/biomarker-market-1941) Technologies Market. With the advent of next-generation sequencing and other genomic technologies, researchers are now able to identify and validate biomarkers with unprecedented accuracy. This progress is crucial for the development of personalized medicine, which is gaining traction in South Korea. The government has allocated substantial funding to genomic research initiatives, aiming to position the country as a leader in this field. As a result, the market for biomarker technologies is anticipated to expand, driven by the need for innovative diagnostic solutions that can cater to the unique genetic profiles of patients. Furthermore, collaborations between academic institutions and biotech companies are likely to foster the discovery of novel biomarkers, further enhancing the market landscape.

### Supportive Regulatory Environment

The supportive regulatory environment in South Korea is a key driver for the South Korea Biomarker Technologies Market. The government has established frameworks that encourage innovation and expedite the approval process for new biomarker-based diagnostics. Regulatory agencies are actively working to streamline the pathways for biomarker validation and commercialization, which is essential for fostering market growth. Recent initiatives have focused on enhancing collaboration between regulatory bodies and industry stakeholders, ensuring that new technologies can be brought to market efficiently. This proactive approach is likely to attract investment in biomarker research and development, as companies seek to capitalize on the favorable regulatory landscape. As a result, the South Korea Biomarker Technologies Market is expected to flourish, driven by the continuous introduction of novel biomarker applications that meet regulatory standards.

### Rising Demand for Personalized Medicine

The increasing demand for personalized medicine is a crucial factor driving the South Korea Biomarker Technologies Market. Patients and healthcare providers are increasingly seeking tailored treatment options that consider individual genetic and molecular profiles. Biomarkers play a vital role in this paradigm shift, enabling more precise diagnoses and targeted therapies. The South Korean healthcare system is adapting to this trend by promoting the integration of biomarker technologies into routine clinical practice. Recent surveys indicate that a significant portion of healthcare professionals supports the use of biomarkers for treatment decisions. This growing acceptance is likely to stimulate market growth, as pharmaceutical companies and diagnostic laboratories invest in the development of biomarker-based solutions. The emphasis on personalized medicine is expected to reshape the landscape of healthcare in South Korea, further driving the demand for innovative biomarker technologies.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases in South Korea is a pivotal driver for the South Korea Biomarker Technologies Market. As the population ages, conditions such as cancer, diabetes, and cardiovascular diseases are becoming more prevalent. This trend necessitates advanced diagnostic tools and personalized treatment options, which biomarkers can provide. According to recent health statistics, chronic diseases account for over 80 percent of healthcare costs in the country. Consequently, the demand for biomarker technologies that can facilitate early detection and targeted therapies is likely to surge, propelling market growth. The South Korean government has recognized this need and is investing in research and development initiatives aimed at enhancing biomarker applications in clinical settings. This focus on chronic disease management is expected to create a robust market environment for biomarker technologies.

### Growing Investment in Healthcare Infrastructure

The South Korean government's commitment to enhancing healthcare infrastructure is a significant driver for the South Korea Biomarker Technologies Market. Recent policies have focused on increasing healthcare spending, with a particular emphasis on integrating advanced technologies into clinical practice. This investment is expected to facilitate the adoption of biomarker technologies, as healthcare providers seek to improve diagnostic accuracy and patient outcomes. For instance, the government has initiated programs to upgrade laboratory facilities and promote the use of cutting-edge diagnostic tools. As a result, the market for biomarker technologies is likely to experience substantial growth, as healthcare institutions increasingly recognize the value of these innovations in delivering high-quality care. The ongoing development of healthcare infrastructure is poised to create a favorable environment for the proliferation of biomarker applications.

## Future Outlook

The South Korea Biomarker Technologies Market is projected to grow at 8.01% CAGR from 2024 to 2035, driven by advancements in [precision medicine](https://www.marketresearchfuture.com/reports/precision-medicine-market-925), increased R&D investments, and rising healthcare demands.

**New opportunities:**

- Development of personalized biomarker panels for targeted therapies. Integration of AI-driven analytics in biomarker discovery processes. Expansion of biomarker-based diagnostics in emerging therapeutic areas.

By 2035, the market is expected to be robust, driven by innovation and strategic investments.

## Segment Insights

### By Application: Oncology (Largest) vs. Infectious Diseases (Fastest-Growing)

In the South Korea [Biomarker Technologies](https://www.marketresearchfuture.com/reports/biomarker-technologies-market-6150) Market, the Oncology application holds the largest share, driven by the rising cancer prevalence and increasing investments in cancer research and development. Conversely, the Infectious Diseases application is emerging as the fastest-growing segment, reflecting the heightened focus on developing diagnostics in response to global health challenges and the COVID-19 pandemic. The growth trends for these segments are influenced by technological advancements and an increased understanding of biomarkers. Oncology, being a well-established field, benefits from robust funding and infrastructure, while Infectious Diseases is gaining traction due to a shift towards precision medicine and the urgency in addressing infectious outbreaks, thus improving patient outcomes and minimizing healthcare burden.

Oncology (Dominant) vs. Neurology (Emerging)

In the South Korea Biomarker Technologies Market, Oncology is recognized as the dominant application, characterized by its well-integrated diagnostic tools and extensive research backing. This segment leverages advanced techniques like liquid biopsies and genomic profiling, making it pivotal in personalized cancer therapies. On the other hand, Neurology is emerging as a significant area of focus, fueled by increasing awareness of neurodegenerative disorders and the need for early diagnosis and intervention. The advancements in neuroimaging and biomarker identification for conditions such as Alzheimer's disease reflect its growing importance. Both segments signify crucial endpoints in medical innovation, leading to enhanced patient management and treatment pathways.

### By Technology: Genomics (Largest) vs. Proteomics (Fastest-Growing)

The South Korea Biomarker Technologies Market exhibits a diverse range of technological segments, with genomics leading the market share. It has gained significant traction due to the country's robust focus on personalized medicine and advancements in genetic research. Following closely is proteomics which, while smaller in market share, is rapidly gaining attention thanks to applications in disease diagnosis and monitoring. Both technologies are fundamental to the biomarker landscape, enhancing diagnostics and therapeutic development. Growth trends in the South Korean biomarker technology market reveal a competitive landscape where proteomics is emerging as the fastest-growing segment. This rapid expansion is driven by the increasing need for precise biomarkers in drug development, coupled with government support for biotechnological advancements. Additionally, advancements in analytical techniques and a surge in innovative research collaborations are propelling the growth of proteomics, making it a key area of focus in the coming years.

Genomics: Dominant vs. Proteomics: Emerging

In the South Korea Biomarker Technologies Market, genomics is the dominant segment, recognized for its foundational role in modern diagnostics and treatment protocols. Its popularity stems from the burgeoning interest in genetic-based therapies and the capacity to analyze vast genetic data efficiently. On the other hand, proteomics is poised as an emerging segment, characterized by its focus on understanding protein functions and interactions critical for identifying novel biomarkers. The shift towards personalized medicine and targeted therapies emphasizes the importance of proteomics, driving research and commercial interest. Thus, while genomics continues to lead, proteomics is rapidly evolving and attracting investment, positioning itself as a crucial player in the biomarker technology space.

### By End Use: Pharmaceutical Companies (Largest) vs. Research Institutions (Fastest-Growing)

The South Korea Biomarker Technologies Market is characterized by distinct end-use segments where pharmaceutical companies hold the largest market share. These companies leverage biomarker technologies for drug development and personalized medicine, ensuring a significant portion of the market is dedicated to their needs. Conversely, research institutions are swiftly gaining traction, driven by advancements in biomarker discovery and validation processes that are integral to ongoing medical research. As these entities continue to collaborate with biotechnology firms, their presence in the market is expected to increase further.

Pharmaceutical Companies (Dominant) vs. Research Institutions (Emerging)

Pharmaceutical companies are at the forefront of the South Korea Biomarker Technologies Market, utilizing advanced biomarker identification for enhanced drug discovery and efficacy. This dominance stems from their substantial investment in R&D, enabling tailored therapeutic solutions. In contrast, research institutions represent an emerging force by focusing on the innovation of biomarker applications, driven by a collaborative ecosystem of academia and industry. Their ability to produce groundbreaking research fosters rapid advancements in biomarker technologies, positioning them as key players expected to influence market dynamics significantly in the coming years.

### By Product Type: Reagents (Largest) vs. Assays (Fastest-Growing)

In the South Korea Biomarker Technologies Market, the product type segment is diverse, comprising reagents, assays, instruments, and software. Among these, reagents hold the largest market share, primarily due to their essential role in various diagnostic applications. Assays, on the other hand, are quickly gaining traction as the fastest-growing segment, driven by the increasing prevalence of chronic diseases and the demand for advanced diagnostic solutions.

Reagents (Dominant) vs. Assays (Emerging)

Reagents serve as the backbone of the biomarker technologies market, facilitating numerous assays and diagnostic processes. Their dominance can be attributed to their vital role in the detection and analysis of biological markers, crucial for accurate disease identification and monitoring. In contrast, assays represent an emerging force in this market, spurred by innovations in testing methodologies and the growing focus on personalized medicine. These rapid advancements cater to the need for quick and reliable diagnostic solutions, further fueling the market's growth.

## Competitive Benchmarking

The South Korea Biomarker Technologies Market is characterized by a dynamic competitive landscape, driven by rapid advancements in biotechnology and increasing demand for personalized medicine. Key players such as Samsung Biologics (KR), LG Chem (KR), and Celltrion (KR) are at the forefront, leveraging their extensive research capabilities and innovative product pipelines. Samsung Biologics (KR) focuses on biopharmaceutical manufacturing and has been expanding its capabilities to include biomarker development, which positions it strategically within the market. Meanwhile, LG Chem (KR) emphasizes partnerships with research institutions to enhance its biomarker discovery processes, thereby strengthening its competitive edge. Collectively, these strategies foster a robust environment where innovation and collaboration are paramount.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several players vying for market share, yet the influence of major companies is substantial. This competitive structure allows for a diverse range of biomarker technologies to emerge, catering to various therapeutic areas and patient needs.
In January 2026, Celltrion (KR) announced a strategic partnership with a leading global diagnostics firm to co-develop novel biomarker assays aimed at improving cancer diagnostics. This collaboration is likely to enhance Celltrion's product offerings and expand its market reach, reflecting a trend towards strategic alliances that combine expertise in diagnostics and therapeutics. Such partnerships may prove crucial in navigating the complexities of biomarker development and commercialization.
In December 2025, LG Chem (KR) launched a new biomarker platform that utilizes AI-driven analytics to identify potential therapeutic targets more efficiently. This initiative not only underscores LG Chem's commitment to innovation but also positions the company to capitalize on the growing trend of integrating artificial intelligence into biomarker research. The implications of this technology could be profound, potentially accelerating the pace of drug discovery and development.
In November 2025, Samsung Biologics (KR) expanded its research facilities to include advanced genomic sequencing capabilities, which are essential for biomarker identification. This expansion is indicative of the company's long-term strategy to enhance its R&D capabilities and maintain a competitive advantage in the rapidly evolving biomarker landscape. By investing in cutting-edge technologies, Samsung Biologics (KR) is likely to improve its service offerings and attract more partnerships.
As of February 2026, the competitive trends in the South Korea Biomarker Technologies Market are increasingly defined by digitalization, sustainability, and the integration of AI. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it is anticipated that competitive differentiation will evolve, with a shift from price-based competition to a focus on technological advancements, innovation, and supply chain reliability. This transition may ultimately redefine how companies position themselves in the market, emphasizing the importance of agility and responsiveness to emerging trends.

## Recent News & Developments

_Recent news developments in the South Korea Biomarker Technologies Market have highlighted significant advancements and increased investment in the sector. Companies like Korea Biobank and Medytox are expanding their Research and Development efforts to enhance biomarker discovery and diagnostics. Lunit announced collaborations aimed at advancing AI and imaging technologies, aiming to optimize cancer diagnostics. In July 2023, Hanmi Pharmaceutical made notable strides with new biomarker-based therapies targeting specific conditions. Seegene also continues to grow, focusing on diagnostic innovations amidst rising demand.__Current affairs indicate a competitive landscape with medtech firms such as MediKine and LG Chem enhancing their molecular diagnostic solutions. Green Cross Corporation is making efforts in vaccine and__therapeutic developments associated with biomarkers. Notably, in September 2023, Samsung Biologics entered a strategic partnership with Nara Biotech to co-develop innovative biomarker-based technologies. The continuous growth in market valuation is supported by the increasing need for precision medicine, which drives investments in biomarker technologies. Over the last few years, substantial emphasis on genetic research, evidenced by collaborations and funding in bioanalytics, has fueled advancements in the South Korean biotechnology landscape._

## Report Scope

Report Scope:

| Report Attribute/Metric Source: | Details |
| --- | --- |
| MARKET SIZE 2018 | 695.49(USD Million) |
| MARKET SIZE 2024 | 751.2(USD Million) |
| MARKET SIZE 2035 | 1502.4(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.504% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Korea Biobank, Medytox, Lunit, Hanmi Pharmaceutical, Precision Medicine, Seegene, MediKine, LG Chem, Green Cross Corporation, Nara Biotech, Bioasis Technologies, SNUH Biomedical Research Institute, Pharmicell, Samsung Biologics |
| SEGMENTS COVERED | Product, Profiling Technology, Application, Research Area |
| KEY MARKET OPPORTUNITIES | Advanced diagnostics development, Personalized medicine growth, Increasing research funding, Rising disease prevalence, Biotechnology collaboration expansion |
| KEY MARKET DYNAMICS | Rising prevalence of chronic diseases, Increasing investment in R&D, Demand for personalized medicine, Advancements in genomics technology, Growing adoption of point-of-care testing |
| COUNTRIES COVERED | South Korea |

## Frequently Asked Questions

**Q: What is the current valuation of the South Korea Biomarker Technologies Market?**
A: As of 2024, the market valuation was 0.751 USD Billion.

**Q: What is the projected market size for the South Korea Biomarker Technologies Market by 2035?**
A: The market is projected to reach 1.75 USD Billion by 2035.

**Q: What is the expected CAGR for the South Korea Biomarker Technologies Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 8.01%.

**Q: Which application segment is anticipated to have the highest valuation in the South Korea Biomarker Technologies Market?**
A: The Oncology application segment is expected to grow from 0.3 to 0.7 USD Billion.

**Q: How does the Cardiology segment perform in terms of market valuation?**
A: The Cardiology segment is projected to increase from 0.15 to 0.35 USD Billion.

**Q: What are the key technologies driving the South Korea Biomarker Technologies Market?**
A: Key technologies include Genomics, Proteomics, and Bioinformatics, with valuations ranging from 0.1 to 0.45 USD Billion.

**Q: Which end-use segment is likely to dominate the market in the coming years?**
A: Pharmaceutical Companies are expected to lead, with a valuation projected to rise from 0.3 to 0.7 USD Billion.

**Q: What product type is forecasted to show significant growth in the market?**
A: Reagents are anticipated to grow from 0.3 to 0.675 USD Billion.

**Q: Who are the major players in the South Korea Biomarker Technologies Market?**
A: Key players include Samsung Biologics, LG Chem, and Celltrion, among others.

**Q: What trends are influencing the growth of the South Korea Biomarker Technologies Market?**
A: The market growth is influenced by advancements in technology and increasing demand for personalized medicine.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-biomarker-technologies-market-56248*